IFN beta Polyclonal Antibody, Invitrogen™

Description

• Specificity: Neutralizes human interferon beta
• Activity: 2.8x10^5 NU/mL
• Interferon was titrated with the use of the cytopathic effect inhibition assay using A549 cells with EMCV, where 1 unit/mL of interferon was necessary to produce an endpoint of 50%
• One neutralization unit is defined as the amount of serum required to neutralize one unit of human IFN beta to an endpoint of 50%
• Store at -20°C for short-term use (less than 6 months)
• For long-term storage, aliquot and store at -70°C or below for retention of full activity
• Refreezing should be done on dry ice or in a dry ice/alcohol bath
• Further dilution of the product should be in buffers containing protein such as 0.1% BSA
• Packaged by and distributed for PBL Assay Science
• Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response
• IFNs can also inhibit the development of tumors
• IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes
• More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta
• IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.